Drug intelligence / Profile preview

BGC20-0134

Development stage: Discontinued
Lead developer: Bio-Technology General
Modality: Small Molecules
Administration: Oral

Overview

BGC20-0134 (also known as Pleneva) is an orally administered structured lipid that was investigated for the treatment of relapsing-remitting multiple sclerosis (RRMS). Developed by BTG International (later acquired by Boston Scientific), the compound is a synthetic triglyceride designed to deliver specific fatty acids intended to modulate the immune response and provide neuroprotective effects. The drug reached Phase IIa clinical development (NCT00505375), where it was evaluated for its ability to reduce the cumulative number of new gadolinium-enhancing lesions in MS patients. However, the clinical program was terminated by the sponsor and is no longer active in the Boston Scientific pipeline.

Brand names: Pleneva
Other names: Structured Lipid

Beyond the preview

Go deeper on BGC20-0134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGC20-0134.

Explore the full profile